iiinova — where your digital self keeps evolving

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

We are excited to share our paper describing neutralising monoclonal antibodies against human coronavirus NL63, an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally only causes mild respiratory illness. www.nature.com/articles/s44...

nature.com

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus - npj Viruses

npj Viruses - Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus

152

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

1/ Hot off the press in @jimmunol.bsky.social. We investigated how same side (ipsilateral) vs alternate side (contralateral) prime-boost vaccination impacts germinal center (GC) dynamics & antibody responses against SARS-CoV-2 spike in mice.💉🦠#immunology #vaccines @thedohertyinst.bsky.social

133

ViralVax Lab @viralvaxlab.bsky.social · 10/01/2025

Check out the latest from @skentskent.bsky.social and team - how does co-administration of influenza and COVID-19 vaccines affect immunity? Congrats to Wen Shi Lee, Kevin Selva and Jen Audsley on a great study and collaboration between the ViralVax and Chung labs! insight.jci.org/articles/vie...

010